1. Cell Cycle/DNA Damage
  2. CDK

Roscovitine (Synonyms: CYC202; R-roscovitine; Seliciclib)

Cat. No.: HY-30237 Purity: 99.77%
Data Sheet SDS Handling Instructions

Roscovitine is a potent and selective CDK inhibitor with IC50 of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.

For research use only. We do not sell to patients.
Roscovitine Chemical Structure

Roscovitine Chemical Structure

CAS No. : 186692-46-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $66 In-stock
10 mg $60 In-stock
50 mg $150 In-stock
100 mg $200 In-stock
200 mg $280 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Roscovitine is a potent and selective CDK inhibitor with IC50 of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.

IC50 & Target

IC50: 0.2 μM (CDK5), 0.65 μM (Cdc2), 0.7 μM (CDK2)[1]

In Vitro

Roscovitine displays high efficiency and high selectivity towards some cyclin-dependent kinases. The kinase specificity of Roscovitine is investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl). Most kinases are not significantly inhibited by Roscovitine. Cdc2, Cdk2, and Cdk5 only are substantially inhibited (IC50 values of 0.65, 0.7, and 0.2 μM, respectively). Cdk4k and Cdk6 are very poorly inhibited by Roscovitine (IC50>100 μM). Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, respectively. Roscovitine inhibits the proliferation of mammalian cell lines with an average IC50 of 16 μM[1]. Roscovitine decreases the level of CDK5 and p35 with upregulation of E-cadherin, but downregulation of Vimentin and Collagen IV. Moreover, Roscovitine inhibits the ability of high glucose cultured NRK52E cells to migrate and invade[2].

In Vivo

Compare with normal controls, Roscovitine downregulates phosphorylated ERK1/2 and PPARγ with concomitant increase in E-cadherin, but decrease in Vimentin and Collagen IV. Correspondingly, Roscovitine decreases renal tubulointerstitial fibrosis of diabetic rats. Roscovitine is effective in decreasing tubulointerstitial fibrosis via the ERK1/2/PPARγ pathway in diabetic rats[2]. Roscovitine (16.5 mg/kg) significantly reduces the rate of tumor growth and increases survival of treated mice. Strikingly, Roscovitine treatment leads to complete tumor disappearance in one mouse (25%); moreover, no tumor regrowth in this mouse is found 5 months after completion of the treatment. Mouse weights do not differ significantly between mice treated with Roscovitine and control mice, and behavioral differences between the two groups are also negligible. These results suggest that Roscovitine can be used effectively as a selective tumor growth inhibitor in HPV+ head and neck cancer[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02160730 Shlomo Melmed, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Cedars-Sinai Medical Center Cushings Disease May 2014 Phase 2
NCT02649751 University Hospital, Brest|ManRos Therapeutics|Cyclacel Pharmaceuticals, Inc. Cystic Fibrosis February 2016 Phase 2
NCT00999401 Cyclacel Pharmaceuticals, Inc. Advanced Solid Tumors April 2009 Phase 1
NCT01333423 M.D. Anderson Cancer Center|National Institutes of Health (NIH) Breast Cancer September 2012 Phase 1
NCT00372073 Cyclacel Pharmaceuticals, Inc. Non-small Cell Lung Cancer July 2006 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.8213 mL 14.1064 mL 28.2127 mL
5 mM 0.5643 mL 2.8213 mL 5.6425 mL
10 mM 0.2821 mL 1.4106 mL 2.8213 mL
Cell Assay

Roscovitine is dissolved in DMSO and stored, and then diluted with appropriate media before use[2].

Rat kidney tubular epithelial cells (NRK52E) are used. CDK5 inhibitor Roscovitine (Ros.; 10 μM) and activator p35 (15 μM), PPARγ agonist Rosiglitazone (Rosi.; 50 nM), and ERK1/2 inhibitor U0126 (50 nM) are used to treat NRK52E cells. Cells in each group are treated for 72 hours and then harvested for further analyses[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Roscovitine is dissolved in DMSO and stored, and then diluted with water or PBS (Mice and Rat)[2][3].

Male Sprague Dawley rats (6-8 weeks of age) are given intraperitoneally a single injection of either Streptozotocin (65 mg/kg) diluted in 0.1 M citrate buffer pH 4.5 (diabetic) or citrate buffer (non-diabetic). Plasma glucose concentrations are determined using the glucose oxidase method on a glucose analyzer three days after the injection. Rats with a glucose level over 16.7 mM are considered diabetic and thus included in the study. Plasma glucose level is measured once every week. To investigate the effect of CDK5 inhibition on renal tubulointerstitial fibrosis, Roscovitine (25 mg/kg) is injected peritoneally to diabetic rats every day till sacrifice. DMSO is included as controls.
Exponentially growing UMSCC47 cells are injected subcutaneously into the sacral area of female NUDE mice. Each mouse is inoculated with 2×105 cells in 50% matrigel and 50% PBS at a volume of 100 μL. After tumors reach a measurable size, the mice are given 16.5 mg/kg doses of intraperitoneal Roscovitine or vehicle injections. Body weight, tumor growth, and general behavior are monitored. Tumor volumes are measured every 3 days. Mice are sacrificed when the tumor exceeded a size of 0.5cm3. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.77%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: